Sidley-Steered Roche To Buy Biopharma Biz For Up To $1.5B
Swiss multinational Roche said Tuesday that it has agreed to acquire Poseida Therapeutics, a U.S. genetic engineering company, for up to $1.5 billion in cash to bolster the healthcare giant's range...To view the full article, register now.
Already a subscriber? Click here to view full article